AstraZeneca PLC has announced that the U.S. Food and Drug Administration (FDA) has approved its drug Imfinzi (durvalumab) in combination with enfortumab vedotin (EV) for the treatment of muscle-invasive bladder cancer (MIBC). This approval is significant as it provides a new option for patients who are ineligible for or have refused cisplatin-based chemotherapy, a standard treatment for bladder cancer.

The approval is based on data from the VOLGA Phase III trial, which demonstrated a 49% reduction in the risk of disease recurrence and a 42% reduction in the risk of death. This new treatment regimen is expected to change the landscape of bladder cancer treatment, potentially setting a new standard of care for patients.

Background

AstraZeneca PLC, incorporated in the UK, is a leading global biopharmaceutical company specializing in the development of innovative medicines. The company operates in the Pharmaceutical Preparations sector (SIC: 2834) and is listed on the New York Stock Exchange under the ticker AZN. Recent filings include several 6-K forms, indicating ongoing updates related to their operations and product approvals.

What the Filing Says

The SEC filing dated November 16, 2026, details the FDA's approval of the Imfinzi and EV combination for MIBC. The approval is particularly noteworthy as it allows for a neoadjuvant treatment followed by adjuvant therapy after radical cystectomy, a surgical procedure to remove the bladder. The filing states, "This approval brings the first perioperative immunotherapy regimen where enfortumab vedotin is administered only in the neoadjuvant setting to patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy."

Impact

This approval is expected to have a profound impact on patients suffering from muscle-invasive bladder cancer, particularly those who cannot tolerate traditional cisplatin chemotherapy. With around 16,000 patients diagnosed with MIBC in the U.S. annually, this new treatment option could significantly improve survival rates and quality of life for many. Furthermore, this advancement may compel AstraZeneca's competitors in the oncology space to reevaluate their treatment offerings and strategies.

What's Next

While the filing does not specify future actions, it is anticipated that AstraZeneca will continue to pursue regulatory approvals in other regions, including the European Union and Japan, based on the positive outcomes of the VOLGA trial.

“Today's approval offers a novel Imfinzi-based regimen that almost halved the risk of disease recurrence and reduced the risk of death by 42 percent in the VOLGA trial,” said Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca.